Serum Adinopektin Düzeylerinin İskemik İnmedeki Rolü

Amaç: Ateroskleroz, iskemik inmede majör risk faktörlerindendir. Yağ dokudan üretilen, aterosklerozu gerileten adiponektinin; obezite, hipertansiyon, diyabet, hiperlipidemi gibi ateroskleroz risk faktörlerinin varlığında serum düzeylerinin azaldığı ortaya konulmuştur. Bu çalışmada iskemik inmeli hastalarda serum adiponektin değerlerini ve şuur düzeyi ile olan ilgisini incelemeyi amaçladık.Gereç ve Yöntem: Çalışmaya inme sonrası ilk 24 saati içerisinde başvuran, 45 yaş üstü akut iskemik inmeli 17 hasta alındı ve benzer yaştaki 22 sağlıklı kontrol grubu ile karşılaştırıldı. Hastaların ilk 24-48. saatlerinde alınan serum örneklerinde adiponektin düzeyleri ölçüldü ve bilinç düzeyleri Glaskow koma skoru ile değerlendirildi. Sonuçlar: Sağlıklı olgularda adiponektin düzeyi 17.16 ± 0.9 microg/mL iken iskemik inme grubunda 8.80 ± 0.7 microg/mL tespit edildi ve aralarındaki fark istatistiksel olarak anlamlı idi (p

The Role of Serum Adiponectin Levels on Ischemic Stroke

Purpose: Atherosclerosis is among the major factors in ischemic stroke. It has been set forth that in the presence of adiponectin, which is produced from adipose tissue and downgrades athesclerosis, and of atherosclerosis risk factors such as obesity, hypertension, diabetes, and hyperlipidaemia, serum levels decline. In this study, we aimed at examining the relation between the serum adiponectin value and level of consciousness in patients with ischemic stroke.Method: 17 patients with acute ischemic stroke, who applied within the 24 hours after stroke and who are above the age of 45, were involved in the study and compared to the 22 healthy control group of similar age. The levels of adiponectin were measured in the serum samples of the patients taken within the first 24-48th hours of the patients and their levels of consciousness were evaluated with Glasgow coma score.Results: While adiponectin level is 17.16 ± 0.9 microg/mL in healthy cases, 8.80 ± 0.7 microg/mL has been found in ischemic stroke group and the difference between them was statistically significant (p

___

  • Kumral E, Balkır K. Inme epidemiyolojisi. In: Balkan S, editör. Serebrovasküler hastalıklar. 1. baskı, Ankara: Güneş Kitapevi; 2002. pp. 38-40.
  • Lewandowski C, Barsan W. Treatment of acute ischemic stroke. Ann Emerg Med 2001;37:202-16.
  • Onat A., Keleş İ, Çetinkaya A, et al. On Yıllık TEKHARF Çalışması Verilerine Göre Türk Erişkinlerinde Koroner Kökenli Ölüm ve Olayların Prevalansı Yüksek. Türk Kardiyol Dern Arş 2001;29:8-19.
  • American Heart Association. Heart Disease and Stroke Statistics—2006 Update. Dallas, Tex: American Heart Association.
  • Marmot MG, Poulter NR: Primary prevention of stroke. Lancet 1992, 339: 344-347.
  • Zuber M, Mas JL: Epidemiologie des accidents vasculaires cerebraux. Rev Neurol 1992, 148: 245-255.
  • Maeda K, Okubo K, Shimomura I, Funahashi T, Matsuzawa Y &Matsubara K. cDNA cloning and expression of a novel adipose specific collagen-like factor, apM1 (adipose most abundant gene transcript 1). Biochemical and Biophysical Research Communications 1996 221 286–289.
  • Faraj M, Havel PJ, Phelis S,Blank D, Sniderman AD, Cianflone K, plasma acylation – stimulating protein adiponectin , leptin, and ghrelin before and weight loss induced by gastric bypass surgery in morbidly obese subjects.J Clin Endo.Metab. 2003; 88: 1594 – 1602.
  • M. Sasaki, T. Kawano and T. Saito et al., Hypoadiponectinemia in patients with cerebral infarction: comparison with other atherosclerotic disorders, Am J Med Sci 333 (2007), pp. 140–144.
  • Chamorro A. Role of inflammation in stroke and atherothrombosis. Cerebrovasc Dis. 2004; 17 (suppl 3): 1–5.
  • Rosenson RS. Statins in atherosclerosis: lipid-lowering agents with antioxidant capabilities. Atherosclerosis 2004; 173: 1-12.
  • Yang CY. Calcium and magnesium in drinking water and risk of death from cerebrovascular disease. Stroke 1998, 29(2): 411-414.
  • Kappanen H, Pennanen R, Passinen L. Minerals, coronary heart diseae and sudden coronary death. Adv Cardiol 1978, 25:9.
  • Ouchi N, Kihara S, Arita Y, Nishida M, Matsuyama A, Okamoto Y. Adipocyte-derived plasma protein, adiponectin, suppresses lipid accumulation and class A scavenger receptor expression in human monocyte-derived macrophages. Circulation 2001; 103:1057–1063.
  • Shand BI, Scott RS, Elder PA, George PM. Plasma adiponectin in overweight, nondiabetic individuals with or without insulin resistance. DM Obes Metab 2003; 5:349-353.
  • Homoscysteine and risk of ischemic heart disease and stroke: a meta analyisis. JAMA 2002;288:2015. [PMID:12387654]
  • The Fifth Report of The Joint National Committee on detecıtion evaluation and treatment of high blood pressure. Arch Intern Med 1993, 153-161.